key: cord-0803261-7qog7qcy authors: Shokouhi, Shervin; Barati, Saghar; Kazeminia, Neda; Jamali, Faezeh; Roshan, Baran; Sahraei, Zahra title: Evaluating the Elimination Status of Medications Used for COVID-19 During Hemoperfusion and Therapeutic Plasma Exchange: A Review date: 2021-04-21 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2021.107707 sha: 7fc67b01bf36b9ad08e4e5bb14a29289b7d96284 doc_id: 803261 cord_uid: 7qog7qcy Since late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, better known as COVID-19) has rapidly spread worldwide. The primary pathophysiology by which COVID-19 leads to severe lung damage is cytokine releasing syndrome (CRS), which can cause death. Therefore, removing cytokines via therapeutic plasma exchange or hemoperfusion could be a therapeutic approach to treat CRS. However, hemoperfusion or therapeutic plasma exchange could alter the effectiveness of concomitant medications. Thus, concomitant medication doses might need to be adjusted to prevent their elimination via therapeutic plasma exchange or hemoperfusion, thus ensuring that these medications remain effective. This narrative review investigates the elimination status of current medications used to manage COVID-19 during hemoperfusion and therapeutic plasma exchange, with a focus on their pharmacokinetic profiles. COVID-19 is a fulminant disease that is often accompanied by acute respiratory distress syndrome (ARDS), acute thrombosis, sepsis, and end-organ failure [1, 2] . Different strategies have been employed to manage these conditions, with early interventions including oxygenation, coagulation modifications, antiviral and immunologic therapy. The primary pathophysiology by which COVID-19 leads to severe lung damage-followed by death-is cytokine releasing syndrome (CRS), or cytokine storms leading to multi-organ failure (MOF) [2] . It progresses rapidly and has a high mortality rate. Therefore, the removal of cytokines via therapeutic plasma exchange (TPE) or hemoperfusion (HP) could be a viable therapeutic option for those infected by COVID-19. However, HP and TPE may significantly alter the pharmacokinetic profiles of concomitant medications that patients might be given to treat COVID- 19 . These medications might even be eliminated, meaning that no therapeutic benefits will be achieved. Hence, the potential elimination of other medications that the patient receives while on TPE or HP needs to be considered. In this narrative review, we searched Pubmed, Scopus, and Web of Science databases to gather data regarding the pharmacokinetic profiles of medications prescribed to COVID-19 patients during TPE or HP. This review could help healthcare providers make better decisions regarding the timing of medication administration. HP is an extracorporeal blood purification modality that selectively removes abnormal cells, components, and cytokines in the blood due to specific disease states [3, 4] . In acute inflammatory situations, such as COVID-19, hemoperfusion with HA330 cartridges effectively removes cytokines [3] . However, HP can also reduce the blood concentration of concomitant medications used to treat COVID-19. Hence, the evaluation and prediction of drug removal by HP are crucial issues. TPE is an extracorporeal process for removing and exchanging blood plasma directly by mechanical, immunoprecipitation, cryoprecipitation, or filtration techniques [5] . In TPE, the patient's blood is passed through an apheresis device. The filtered plasma is removed and discarded, while red blood cells are reinfused and physiologic fluids, such as plasma or albumin, are replaced [6] . Data show that TPE can impact the clinical stabilization and improvement of critically ill COVID-19 patients [7] . Moreover, TPE can also be well-tolerated without any adverse effects while reducing levels of key pro-inflammatory cytokines [7] . In addition to removing cytokines, TPE and HP can remove drugs circulating in plasma compartments. Hence, the therapeutic levels may fluctuate to subtherapeutic levels, and serum concentration levels should be measured if possible. However, to the best of our knowledge, few trials have measured the concentrations of drugs used to treat COVID-19 during TPE or HP [6, 8, 9] . Drug removal by TPE is a multifactorial phenomenon that can be affected by the pharmacokinetic characteristics of the drug. Several parameters that affect drug removal by TPE include plasmaprotein binding, molecular weight, the volume of distribution (V d ), half-life, and extracorporeal clearance. Among all these parameters, a low volume of distribution (V d ) (i.e., <0.2 L/kg) and a high rate of protein binding (i.e., >80%) strongly affect drug removal during TPE [6, 9] . Generally, medications with a volume of distribution of <0.2 L/kg or plasma protein binding of >80% are most likely to be removed during TPE [6] . It is believed that TPE might have a slight impact on drug removal when endogenous clearance is less than 4 mL/min and the drug half-life is longer than 2 hours. We tried to gather information regarding these characteristics and the pharmacokinetic profiles of medications currently used to treat COVID-19. The collected data could lead to better predictions of whether a specific medication will be removed via TPE/HP (Table 1 ). HP removes drugs by directly binding to the sorbent material in the adsorption cartridge containing neutro-macroporous resin adsorbing beads [4] . Several types of cartridges with a wide pore size distribution are available for various conditions. These include HA130 (pore size distribution = 500-40,000 Da) for chronic conditions, HA230 (pore size distribution = 200-10,000 Da) for intoxication, and HA330 (pore size distribution = 500-60,000 Da) for acute inflammatory conditions such as cytokine storms brought on by COVID-19 [10] . Depending on the pore size, HP can remove broad-spectrum molecular weight drugs up to 60,000 Da [4, 10] . In COVID-19 (as an acute inflammatory condition), HA330 cartridges are used to reduce cytokine storms and inflammation [10] . We attempted to practically unify existing information to prepare a framework of expected variations in plasma concentration levels of medications administered to treat COVID-19 patients undergoing TPE and HP. The findings are summarized in Table 1 . [3] . However, these interventions might remove concomitant medications. Hence, the potential elimination of these medications needs to be evaluated based on their pharmacokinetic profile. Such evaluations could prevent subtherapeutic concentrations of concomitant medications. A variety of medications administered to treat COVID-19 could be removed by TPE. Therefore, it is crucial to consider this elimination and consider the proper timing for administration. The data presented in this review were gathered based on the pharmacokinetic profiles of relevant medications. More clinical trials should be conducted to confirm these results. None. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Coagulopathy in COVID-19 Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert review of respiratory medicine Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review. Archives of academic emergency medicine A new series of sorbent devices for multiple clinical purposes: current evidence and future directions. Blood purification A resin artificial kidney. The Journal of laboratory and clinical medicine Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review Experience with fixed-bed charcoal haemoperfusion in the treatment of severe drug intoxication. Archives of toxicology Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. in Seminars in Dialysis Drug removal by plasmapheresis: an evidence-based review Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis Treating HCV with ribavirin analogues and ribavirin-like molecules The clinical pharmacology of ribavirin. in Seminars in liver disease Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS neglected tropical diseases Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection Role of favipiravir in the treatment of COVID-19 USE OF REMDESIVIR IN PATIENTS WITH COVID-19 ON HEMODIALYSIS-A STUDY OF SAFETY AND TOLERANCE Population pharmacokinetic/pharmacodynamic analyses of lopinavir and ritonavir in subjects receiving the tablet formulation. HIV Expert opinion on pharmacotherapy Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF COBICISTAT AND ATAZANAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection Clinical pharmacokinetics of interferons Pharmacokinetics of intravenous immunoglobulin: a systematic review In vivoAdministration of Intravenous Immunoglobulin (IVIg) can Lead to Enhanced Erythrocyte Sequestration Pharmacokinetics and Pharmacodynamics of Dexamethasone after Intravenous Administration in Camels: Effect of Dose. Veterinary Research Communications Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults Not applicable. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Not applicable.